| Literature DB >> 26185114 |
Abstract
In this issue of Blood, Dombret et al report the final analysis of the international phase 3 study of azacitidine vs conventional care regimens in older (≥65 years), newly diagnosed acute myeloid leukemia (AML) patients with >30% bone marrow blasts and white blood cell (WBC) counts ≤15 × 109/L (AZA-AML-001 study).Entities:
Mesh：
Substances：
Year: 2015 PMID： 26185114 DOI： 10.1182/blood-2015-06-648071
Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113